In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ContraVac's post-vasectomy home sperm test

This article was originally published in Clinica

Executive Summary

SpermCheck Vasectomy, a diagnostic which confirms men's post-vasectomy sterility, has been granted 510(k) clearance from the US FDA. The device, manufactured by Charlottesville, Virginia-based ContraVac, will enable men to test their fertility status at home, in a procedure the company describes as similar to a home pregnancy test for women. It is the first at-home diagnostic to receive FDA approval for sperm testing after vasectomy. SpermCheck Vasectomy is designed to improve the compliance rate for post-vasectomy sterility testing. Around 500,000 vasectomies are performed each year in the US and most patients are asked to undergo two post-vasectomy sperm tests. Currently, nearly 35% of patients never return to the doctor's surgery or lab for their first test and over 70% do not return for their second. The diagnostic will be launched in the US in mid-2008.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts